Cardihab and Roche Diagnostics Partner on Cardiovascular Disease : MTPConnect

21 July 2023

Digital health company Cardihab has recently announced a partnership with Roche Diagnostics Australia Pty Ltd that is focused on improving quality and standards of care, that deliver better outcomes for people living with cardiovascular conditions in Australia.

Cardihab has developed a scientifically validated Digital Cardiac Rehabilitation (DCR) solution that uses smartphone apps and web portals to give clinicians the ability to deliver more convenient, flexible and engaging cardiac rehabilitation services to patients. And through MTPConnect’s Targeted Translation Research Accelerator (TTRA) program, and the support of the TTRA Partner, ANDHealth, the company is now co-designing a new technology enabled program for people with Heart Failure.

“We are thrilled to partner with Roche, who share our passion for making a difference to the way care is delivered in Australia, and who value collaboration to drive change through innovative approaches,” said Cardihab CEO, Helen Souris.

“The complementary nature of Roche’s diagnostic portfolio together with Cardihab’s digital therapeutic solutions will accelerate our ability to realise our purpose of providing patients with the care they need in ways that work for them,” said Ms Souris.

Roche sees this partnership as an integral part of their mission to deliver value-based health care along the entire patient journey, from diagnosis, through treatment and monitoring. An optimised care approach for people living with cardiovascular disease (CVD) has the potential to provide an improved care pathway that has been shown to reduce rates of hospital readmission, costs, and the burden of disease on patients quality of life.

"We are committed to improving care access and outcomes for cardiac patients across Australia by leveraging our strengths and augmenting our offerings to deliver patient centric integrated solutions. We see Cardihab as a great organisation to collaborate with in realising this vision,” said Allison Rossiter, Managing Director of Roche Diagnostics Australia.”

Cardiovascular disease (CVD) is one of the leading causes of death and disability in Australia. According to the Australian Bureau of Statistics, in 2019, CVD accounted for 25% of all deaths in the country¹.

Launched as a joint venture between CSIRO and the Queensland Government in 2016, Cardihab began as pioneers in cardiovascular disease management, founded in real world evidence. The company has 8+ years of experience developing digitally enabled models of care and healthcare platforms, alongside clinicians.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. As part of the Roche Group, Roche Diagnostics Australia is a leading healthcare company that is committed to better outcomes for everyone in Australia.